ClinicalTrials.Veeva
Menu

Find clinical trials for Multiple Myeloma in Warszawa, Mazowieckie

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Plasma Cell Cancer
Lymphoma
Hematologic Cancer
Cancer
Leukemia
Smoldering Multiple Myeloma
Non-Hodgkin Lymphoma

Multiple Myeloma trials near Warszawa, Mazowieckie, POL:

Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma (BOSTON)

low-dose dexamethasone (SVd) versus bortezomib plus low-dose dexamethasone (Vd) in adult patients with RRMM who have received 1 to 3 prior anti-multiple...

Active, not recruiting
Multiple Myeloma
Drug: Selinexor
Drug: Dexamethasone

Phase 3

Karyopharm Therapeutics
Karyopharm Therapeutics

Warsaw, Poland and 156 other locations

monotherapy (control) in participants with newly diagnosed multiple myeloma after undergoing autologous stem cell transplant. In Pa...

Enrolling
Multiple Myeloma
Drug: Elranatamab
Drug: Lenalidomide

Phase 3

Pfizer
Pfizer

Warszawa, Poland and 210 other locations

(Arm A) versus daratumumab in combination with bortezomib/dexamethasone (Arm B) in the participants with relapsed recurrent multiple myeloma...

Active, not recruiting
Multiple Myeloma
Drug: Daratumumab
Drug: Belantamab mafodotin

Phase 3

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Warszawa, Poland and 150 other locations

compared with VMP alone in participants with previously untreated multiple myeloma who are ineligible for high dose chemotherapy an...

Active, not recruiting
Multiple Myeloma
Drug: Dexamethasone
Drug: Daratumumab IV

Phase 3

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

Warszawa, Poland and 164 other locations

Locations recently updated

with dexamethasone and daratumumab (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in participants with relapsed or refractory multiple...

Enrolling
Multiple Myeloma
Drug: Bortezomib
Drug: Daratumumab

Phase 3

Celgene
Celgene

Warszawa, Poland and 256 other locations

This open-label, randomized study for evaluating the efficacy and safety of single agent belantamab mafodotin when compared to pom/dex in participant...

Active, not recruiting
Multiple Myeloma
Drug: Belantamab mafodotin
Drug: Pom/dex (Pomalidomide plus low dose Dexamethasone)

Phase 3

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Warszawa, Poland and 140 other locations

This study aims to evaluate alternative dosing regimens of single-agent belantamab mafodotin in participants with relapsed or refractory multiple...

Active, not recruiting
Multiple Myeloma
Drug: Belantamab mafodotin

Phase 2

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Warszawa, Poland and 97 other locations

Elranatamab is a bispecific antibody: binding of elranatamab to CD3-expressing T-cells and BCMA-expressing multiple myeloma cells c...

Enrolling
Multiple Myeloma
Drug: Daratumumab
Drug: Dexamethasone

Phase 3

Pfizer
Pfizer

Warszawa, Mazowieckie, Poland and 71 other locations

PREDATOR is a study investigating a role of preemptive daratumumab therapy for preclinical relapse or progression of multiple myeloma...

Enrolling
Multiple Myeloma
Drug: Daratumumab 20 MG/ML [Darzalex]

Phase 2

Polish Myeloma Consortium

Warszawa, Mazowieckie, Poland and 1 other location

The purpose of this study is to evaluate the efficacy and safety of talquetamab in participants with relapsed or refractory multiple myeloma...

Enrolling
Hematological Malignancies
Drug: Talquetamab

Phase 2

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

Warszawa, Poland and 75 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems